Hepatitis C Vaccine Delivered By Inovio Biomedical's Electroporation System Shows Increased T-Cell Responses And Reduced Viral Loads, Study Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB, reported additional interim results from its ongoing phase I/II clinical study of its ChronVac-C� therapeutic DNA vaccine, which is delivered using Inovio's electroporation-based DNA delivery system.
Source: www.medicalnewstoday.com
# posted by Network @ 10:00 AM
